Intas gets USFDA warning over data integrity, quality lapses at Dehradun plant

Intas Pharmaceuticals is facing renewed regulatory pressure in the US after the Food and Drug Administration (FDA) issued a warning letter to its Dehradun facility, flagging serious lapses in quality systems and data integrity that could we
Read more...